GT Biopharma Reports Second Quarter 2025 Financial Results
GTBPSAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced second quarter 2025 financial results for the period ended June 30, 2025.
EXCLUSIVE: GT Biopharma Tells Benzinga 'The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts'
GTBPEXCLUSIVE: GT Biopharma Tells Benzinga 'Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2'
GTBPEXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results
GTBPGTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
EXCLUSIVE: GT Biopharma Tells Benzinga Co. Advances GTB-3650 Phase I Trial To Cohort 2 Following Successful Initial Human Dosing And Evidence Of Early Immune Activation Signals
GTBPGT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate
GTBPGT Biopharma Appoints Michael Breen As CEO For Two-Year Term
GTBPGT Biopharma Files Request For Withdrawal With SEC With Respect To Withdrawal Of Form S-1 Registration Statement, Filed On Dec. 23
GTBPGT Biopharma Q3 EPS $(1.53) Up From $(1.77) YoY
GTBPWhat's Going On With GT Biopharma Stock Tuesday?
GTBPGT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules.
GT Biopharma Shares Resume Trade
GTBPGT Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 3.97%
GTBPGT Biopharma Announces $3.2M Registered Direct Offering Of 740,000 Shares Of Common Stock At A Price Of $4.35 Per Share Under Nasdaq Rules
GTBPWhat's Going On With GT Biopharma Stock?
GTBPGT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top trending tickers on Stocktwits which may point to a rally led by retail traders. According to data from Benzinga Pro, more than 60.4 million shares have been traded in the session, far exceeding the stock's 100-day average of less than 11,000 shares.
GT Biopharma Shares Resume Trading
GTBPGT Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 197.8%
GTBPGT Biopharma Shares Resume Trade
GTBPGT Biopharma Shares Halted On Circuit Breaker To The Downside, Stock Now Up 141.7%
GTBPHC Wainwright & Co. Maintains Buy on GT Biopharma, Lowers Price Target to $5
GTBP